Nneoma Obiejemba, MD
Allergy & Immunology · Rockville, MDNPI 1346664653
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,685 of the $10,812 with a category attached, or 89.6%. It is spread thinly across 29 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations.
Across 419 payments — averaging $25.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AstraZeneca$2K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$781
- Alk-abello, Inc$710
- Pfizer$623
- plus $4K from 23 others
What the payments were for
- Speaking & faculty fees$3003%
- Grants$7006%
- Food & beverage$9,68590%
- Education$1271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 55 | $2,003 |
| AstraZeneca | 75 | $1,833 |
| GSK | 60 | $1,258 |
| Regeneron Healthcare Solutions, Inc. | 28 | $781 |
| Alk-abello, Inc | 11 | $710 |
| Pfizer | 36 | $623 |
| CSL Behring | 25 | $576 |
| Biocryst US Sales Co., LLC | 25 | $550 |
| Grifols USA, LLC | 17 | $383 |
| Genentech USA, Inc. | 13 | $342 |
| Amgen | 12 | $289 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $259 |
| Optinose US, Inc. | 14 | $258 |
| Kaleo, Inc. | 12 | $243 |
| Novartis | 7 | $169 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Boehringer Ingelheim | 4 | $88 |
| Shire North American Group Inc | 1 | $73 |
| Octapharma USA, Inc. | 1 | $47 |
| Blueprint Medicines Corporation | 2 | $41 |
| Hikma Pharmaceuticals USA | 2 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $25 |
| Mylan Specialty L.p. | 1 | $25 |
| Ionis Pharmaceuticals, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Merck | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Pharming Healthcare, Inc. | 1 | $16 |
| USWM, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,812 in reported general payments places this provider in the 80th percentile of 105 allergy & immunology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $46,416 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $38,959 |
| Spiriva RespimatTiotropium Bromide | 17 | $11,241 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $10,501 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $10,217 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $9,108 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $6,925 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,810 |
| Ipratropium Bromide | 102 | $3,700 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 26 | $3,455 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $3,382 |
| Azelastine Hcl | 38 | $2,092 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $1,924 |
| Montelukast Sodium | 113 | $1,798 |
| Epinephrine | 13 | $1,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $1,258 | $56,10083 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $1,833 | $17,31144 claims |
| Boehringer IngelheimSpiriva Respimat | $88 | $11,24117 claims |
| Hikma Pharmaceuticals USAEpinephrine | $28 | $1,62813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 105 allergy & immunology providers in Maryland.
Other allergy & immunology in Rockville
- Sudhir SekhsariaRockville$87K
- Kristin SokolRockville$62K
- Rachel SchreiberRockville$48K
- Julia SohnRockville$16K
- Paul KeiserRockville$7K
- Jordana GoldmanRockville$6K
- Gina Dapul-HidalgoRockville$5K
- Ryan BolotteRockville$4K
- Antoine AzarBaltimore$612K
- Mark ScarupaWheaton$508K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.